RxDoctor Payments Data

Jandrette Rhoe, MD

Family Medicine · Ridgeway, SCNPI 1972691889

Payments from drug & device makers

$4,096in general payments, 2019–2025

Across 105 payments — averaging $39.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Novo Nordisk$795
  • Lilly USA, LLC$534
  • Gilead$429
  • Viiv Healthcare Company$244
  • Abbott$218
  • plus $833 from 15 others

What the payments were for

  • Food & beverage$4,04899%
  • Education$481%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,096 in reported general payments places this provider in the 80th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$81,673
Medicare patients
186
Services billed
1,357

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$155,463
MounjaroTirzepatide43$62,929
EliquisApixaban65$49,377
JardianceEmpagliflozin49$37,611
FarxigaDapagliflozin Propanediol25$22,466
RybelsusSemaglutide14$21,452
Tresiba Flextouch U-100Insulin Degludec12$18,624
TradjentaLinagliptin22$17,589
Breo ElliptaFluticasone/Vilanterol23$14,219
Trelegy ElliptaFluticasone/Umeclidin/Vilanter12$7,715
Advair HfaFluticasone Propion/Salmeterol14$6,247
Humalog Kwikpen U-100Insulin Lispro13$4,631
Albuterol Sulfate HfaAlbuterol Sulfate112$4,310
Lantus SolostarInsulin Glargine,hum.Rec.Anlog31$3,361
Atorvastatin Calcium258$3,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$795$176,914132 claims
Lilly USA, LLCMounjaro$534$62,92943 claims
Boehringer IngelheimJardiance, Tradjenta$127$55,20071 claims
AstraZenecaFarxiga$1,043$22,46625 claims
AbbVieSynthroid$19$1,08916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Ridgeway

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →